AstraZeneca Core EPS Rises 25%; Maintains Revenue Outlook
Wall Street Journal
AstraZeneca said its second-quarter core earnings per share rose to $2.15, and reiterated its 2023 forceast for revenue to increase by a low-to-mid single-digit percentage.